La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

BrainCool Bilan de santé

Santé financière contrôle des critères 4/6

BrainCool possède un total de capitaux propres de SEK165.4M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK182.4M et de SEK17.0M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 58.61m
Fonds propres	SEK 165.40m
Total du passif	SEK 17.01m
Total des actifs	SEK 182.41m

Mises à jour récentes de la santé financière

Recent updates

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

Mar 24

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

Nov 17

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

Jul 23

Is BrainCool (NGM:BRAIN) A Risky Investment?

Mar 07

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BRAIN ( SEK98.4M ) dépassent ses passifs à court terme ( SEK17.0M ).

Passif à long terme: BRAIN n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: BRAIN est sans dette.

Réduire la dette: BRAIN n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 13.9%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BRAIN dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: BRAIN dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 9.5 % chaque année

BrainCool Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

Is BrainCool (NGM:BRAIN) A Risky Investment?

Recent updates

Second quarter 2024 earnings released

Braincool AB (Publ) Approves Board Appointments

BrainCool AB (publ) Announces Roger Henriksson Declines Re-Election as Board Member

BrainCool AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) to Report Fiscal Year 2024 Results on Feb 10, 2025

Full year 2023 earnings released

Braincool AB (Publ) Announces Karolinska Starts the Clinical Study PRINCESS 2 with BrainCool's Product RhinoChill® System

New major risk - Share price stability

BrainCool AB (publ) and University of Freiburg Announces Start of Pivotal Clinical Trial (Cottis 2) for Combined Target Temperature Management and Thrombectomy After Ischemic Stroke

CEO & Director recently sold kr254k worth of stock

Third quarter 2023 earnings released

Braincool AB (Publ) Announces New Clinical Study Evaluating Early Hypothermia Treatment After Cardiac Arrest with the Braincool System and Rhinochill System

CEO & Director recently bought kr53k worth of stock

American Medical Association Approves New Current Procedural Terminology Code for Cryotherapy Using BrainCool's Cooral System

BrainCool AB (publ) Announces New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S

CEO & Director recently bought kr62k worth of stock

Second quarter 2023 earnings released

New major risk - Share price stability

Braincool AB (Publ) Introduces Minichill in Japan

Braincool AB (Publ) Announces New Patent Application for Rhinochill Technology Paves the Way for New Possibilities

BrainCool AB (publ) Receives Patent Approval for "Shivering" in the EU for the Product BrainCool System

Braincool AB (Publ) Announces International Clinical Study with Rhinochill®System of Patients with Sudden Cardiac Arrest Obtain Ethical Approval

First quarter 2023 earnings released

BrainCool AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

BraincCool Launches New Commercialization Strategy for Its Breakthrough Product Cooral ®System Aiming for Reimbursement in the U.S

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

BrainCool AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.17 loss per share (vs kr0.12 loss in 3Q 2021)

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

No independent directors

BrainCool AB (publ) to Report Q3, 2022 Results on Nov 30, 2022

BrainCool AB (publ) Announces FDA approval of Cooral

Second quarter 2022 earnings released: kr0.18 loss per share (vs kr0.13 loss in 2Q 2021)

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.12 loss in 1Q 2021)

BrainCool AB (publ) to Report Q1, 2022 Results on May 31, 2022

No independent directors

CEO & Director recently bought kr73k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

Is BrainCool (NGM:BRAIN) A Risky Investment?

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 2Q 2020)

CEO & Director recently bought kr238k worth of stock

BrainCool AB (publ), Annual General Meeting, Apr 15, 2021

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.43 loss in FY 2019)

BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral® System for Prevention of Oral Mucositis

New 90-day high: kr9.17

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr7.00

Braincool AB Announces Statistically Significant Late-Breaking Clinical Data At SMO Virtual Congress 2020

New 90-day high - kr11.24

BrainCool AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr7.15

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines